PORTLAND, Ore., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) announced that it has licensed to GROH
BEAUTY CORP of Deerfield Beach, Florida, the exclusive worldwide rights to manufacture and distribute its proprietary
GROH® beauty care product line. The license also has a companion agreement that provides for Entia to manufacture
and supply its proprietary ErgoD2® product for use in GROH BEAUTY CORP's manufacture of the various products within the
GROH product line. Together, the license and its companion manufacturing agreement provide Entia with an upfront license fee,
on-going royalties based on sales of products containing the ErgoD2 compound and sales revenue from supply of ErgoD2 to GROH BEAUTY
CORP.
“We are very pleased to be working with GROH BEAUTY CORP, a new business unit of a proven, successful developer and marketer of
beauty and cosmetic products," stated Carl J. Johnson, President and Chief Executive of Entia. “We are confident that they
will generate significant success with the GROH brand and look forward to the additional resources that this license will provide
to us. This is an alternative but superior approach for Entia to the beauty care market and will better contribute to
building value for our shareholders than the Company's previous efforts in this area."
Entia’s 2014 entry into the beauty care market did not achieve the success for which the then management had hoped.
Entia's new management has determined that beauty care is not an appropriate area of strategic focus for the Company, planning
instead upon developing and profitably marketing clinically-proven health care products that are based upon the Company's novel and
proprietary ErgoD2 technology in the nutritional supplement and/or medical food categories.
The Company is taking aggressive yet carefully planned steps toward that end. Dr. Marvin Hausman, Chief Science &
Technology Officer, indicated that Entia plans to introduce its first healthcare product before mid-2017. The product will
likely be introduced as a kidney health supplement. Kidney health is a growing concern in the U.S. and around the
world. "The Company's research studies among individuals with compromised kidney function have been quite encouraging, if not
downright exciting," noted Hausman. "We are anxiously looking forward to the market rollout of the first of our new
healthcare products."
"We are delighted to be working with Entia Biosciences and taking over the GROH brand," said Mr. Patrick Neville of GROH BEAUTY
CORP. "With Entia's proprietary ErgoD2 compound, the products have characteristics that the beauty market will find quite
desirable. We plan on making GROH a big winner."
GROH BEAUTY CORP plans on its initial GROH rollout by midyear. In the interim, GROH products will still be available from
Entia through existing channels.
About Entia Biosciences, Inc.
Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds
that include its revolutionary ErgoD2®. The Company is a leading authority on the clinical effects of oxidative
stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and
medical foods markets. Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is
headquartered in Sherwood, Oregon, a Portland suburb.
About GROH BEAUTY CORP
GROH BEAUTY CORP is a newly established business unit of an international developer, manufacturer and marketer of fine beauty
products. It is based in Deerfield Beach, Florida.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements
that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this
press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange
Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year
ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a
website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the
date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to
publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
Contact: Entia Biosciences, Inc.: Carl Johnson or Tim Timmins (844-559-9910)
